Teradyne [TER] gets its Overweight rating reiterated by KeyBanc
KeyBanc maintained its Teradyne [TER] rating to the equivalent of Overweight but changed the price target to $138 from $115, in a research note dated 2021-01-06. That figure represents around a 13.59% premium from where the company’s shares closed on Tuesday. Other analysts also revised their coverage, with Goldman’s analysts upgrading the shares from “a […]
